NO20081836L - Tumor nekrose faktor reseptor 1 antagonister for behandling av respiratoriske sykdommer - Google Patents

Tumor nekrose faktor reseptor 1 antagonister for behandling av respiratoriske sykdommer

Info

Publication number
NO20081836L
NO20081836L NO20081836A NO20081836A NO20081836L NO 20081836 L NO20081836 L NO 20081836L NO 20081836 A NO20081836 A NO 20081836A NO 20081836 A NO20081836 A NO 20081836A NO 20081836 L NO20081836 L NO 20081836L
Authority
NO
Norway
Prior art keywords
treatment
pulmonary tissue
antagonists
prevention
agent
Prior art date
Application number
NO20081836A
Other languages
English (en)
Inventor
Benjamin P Woolven
Steve Holmes
Ian M Tomlinson
Jennifer Lee
Justian Craig Fox
Mary Frances Fitzgerald
Rudolf M T De Wildt
Gregory P Winter
Armin Sepp
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of NO20081836L publication Critical patent/NO20081836L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SAMMENDRAG Det er beskrevet anvendelse av et middel (f.eks. antistoffragment, antagonist, ligand, dAb-monomer) som binder et mål i pulmonalt vev for fremstilling av en formulering med lang virkning eller langt terapeutisk vindu for lokal levering til pulmonalt vev, og fremgangsmåter for administrering av et middel som binder et mål i pulmonalt vev hos et individ for å fremskaffe et langt terapeutisk vindu i pulmonalt vev. Formuleringen er for, og fremgangsmåten omfatter, lokal administrering til pulmonalt vev. Også beskrevet er anvendelse av antagonister for TNFR1 for fremstilling av en formulering eller medikament for behandling, forebygging eller suppresjon av lungeinflammasjon eller en respiratorisk sykdom og fremgangsmåter for behandling av slike sykdommer. Også beskrevet er anvendelse av midler for fremstilling av en leveringsanordning (f.eks. inhalator, intranasal leveringsanordning) for behandling eller forebygging av lungeinflammasjon eller en respiratorisk sykdom og en leveringsanordning for behandling eller forebygging av lungeinflammasjon eller en respiratorisk sykdom som inneholder et middel som beskrevet her.
NO20081836A 2005-10-24 2008-04-16 Tumor nekrose faktor reseptor 1 antagonister for behandling av respiratoriske sykdommer NO20081836L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0521621.3A GB0521621D0 (en) 2005-10-24 2005-10-24 Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
PCT/GB2006/003935 WO2007049017A2 (en) 2005-10-24 2006-10-23 Agents that bind a target in pulmonary tissue for treating respiratory diseases

Publications (1)

Publication Number Publication Date
NO20081836L true NO20081836L (no) 2008-06-23

Family

ID=35458579

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081836A NO20081836L (no) 2005-10-24 2008-04-16 Tumor nekrose faktor reseptor 1 antagonister for behandling av respiratoriske sykdommer

Country Status (20)

Country Link
US (4) US8129503B2 (no)
EP (1) EP1948694B1 (no)
JP (1) JP2009512672A (no)
KR (1) KR20080066962A (no)
CN (2) CN101346397B (no)
AU (1) AU2006307733B2 (no)
BR (1) BRPI0617771A2 (no)
CA (1) CA2626939A1 (no)
CR (1) CR9933A (no)
EA (1) EA014106B1 (no)
ES (1) ES2688941T3 (no)
GB (1) GB0521621D0 (no)
IL (1) IL190787A0 (no)
MA (1) MA29882B1 (no)
MX (1) MX2008005129A (no)
NO (1) NO20081836L (no)
NZ (1) NZ567441A (no)
TW (1) TW200740848A (no)
WO (1) WO2007049017A2 (no)
ZA (1) ZA200803576B (no)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
DK1888640T3 (da) 2005-05-18 2012-06-18 Ablynx Nv Forbedrede nanobodies mod tumornekrosefaktor-alfa
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
ES2550004T3 (es) 2006-04-04 2015-11-03 Singulex, Inc. Sistema de alta sensibilidad y métodos de análisis de la troponina
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
AU2007310838A1 (en) * 2006-10-27 2008-05-02 Ablynx N.V. Intranasal delivery of polypeptides and proteins
EP1972637B1 (en) 2007-03-19 2011-06-29 Universität Stuttgart huTNFR1 selective antagonists
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
CN101679511A (zh) * 2007-06-06 2010-03-24 杜门蒂斯有限公司 多肽、抗体可变域和拮抗剂
CA2683791A1 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains & antagonists
US20090110679A1 (en) * 2007-07-13 2009-04-30 Luk-Chiu Li Methods and compositions for pulmonary administration of a TNFa inhibitor
WO2009030285A1 (en) * 2007-09-07 2009-03-12 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
JP2011506396A (ja) * 2007-12-13 2011-03-03 グラクソ グループ リミテッド 肺送達用組成物
WO2009089295A2 (en) * 2008-01-07 2009-07-16 Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Anti-hiv domain antibodies and method of making and using same
CA2721202A1 (en) 2008-04-17 2009-10-22 Hilde Adi Pierrette Revets Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
CA2736425A1 (en) * 2008-09-11 2010-03-18 Galapagos Nv Method for identifying compounds useful for increasing the functional activity and cell surface expression of cf-associated mutant cystic fibrosis transmembrane conductance regulator
JP2012509852A (ja) * 2008-11-26 2012-04-26 グラクソ グループ リミテッド ポリペプチド、抗体可変ドメインおよびアンタゴニスト
PT2387583T (pt) * 2009-01-14 2018-12-24 Ablynx Nv Administração pulmonar de domínios de variável única de imunoglobulina e construtos dos mesmos
SG173173A1 (en) 2009-02-19 2011-08-29 Glaxo Group Ltd Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
US8450069B2 (en) 2009-06-08 2013-05-28 Singulex, Inc. Highly sensitive biomarker panels
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
EP2454285A2 (en) * 2009-07-16 2012-05-23 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
US20120107330A1 (en) 2009-07-16 2012-05-03 Adriaan Allart Stoop Antagonists, uses & methods for partially inhibiting tnfr1
CN102686609A (zh) * 2009-10-23 2012-09-19 加文医学研究所 修饰的可变域分子及其生产和使用方法
CA2777312A1 (en) 2009-10-27 2011-05-05 Inusha De Silva Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists
CA2788993A1 (en) 2010-02-05 2011-08-11 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
JP5911848B2 (ja) * 2010-05-04 2016-04-27 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 線維症の検出および処置
EP2603522A1 (en) 2010-08-13 2013-06-19 GlaxoSmithKline Intellectual Property Development Limited Improved anti-serum albumin binding variants
EP2606065A2 (en) 2010-08-20 2013-06-26 GlaxoSmithKline Intellectual Property Development Limited Improved anti-serum albumin binding variants
US8883134B2 (en) 2010-10-20 2014-11-11 Handok Pharmaceuticals, Inc. Human interleukin-1 receptor antagonist—hybrid Fc fusion protein
WO2012072731A2 (en) 2010-12-01 2012-06-07 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
GB2559498B (en) 2011-01-10 2018-10-24 Univ Michigan Regents Stem cell factor inhibitor
US20150018408A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
MY167125A (en) 2011-08-17 2018-08-13 Glaxo Group Ltd Modified proteins and peptides
PE20142405A1 (es) 2012-04-19 2015-01-25 Opko Biolog Ltd Variantes de oxintomodulina de accion prolongada y metodos de produccion de las mismas
US9808534B2 (en) 2012-11-20 2017-11-07 Opko Biologics Ltd. Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
CN103743909B (zh) * 2013-11-29 2015-11-25 漯河医学高等专科学校 弗林蛋白酶抑制剂对肺腺癌细胞生长和转移的影响研究方法
MY184154A (en) 2013-12-12 2021-03-23 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
JP2017538779A (ja) 2014-10-10 2017-12-28 アブリンクス・エヌ・フェー Ｒｓｖ感染の治療方法
SI3204095T1 (sl) 2014-10-10 2019-08-30 Ablynx N.V. Inhalacijska naprava za uporabo pri zdravljenju bolezni dihal z aerosolom
US11097005B2 (en) 2014-12-15 2021-08-24 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
PL3233910T3 (pl) 2014-12-19 2020-06-01 Ablynx N.V. Dimery nanociał połączone cysteiną
DK3292149T3 (da) 2015-05-04 2022-02-28 Cytomx Therapeutics Inc Aktiverbare anti-cd71-antistoffer og fremgangsmåder til anvendelse deraf
AU2016280867B2 (en) 2015-06-19 2020-02-27 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
TWI703158B (zh) * 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
KR102220275B1 (ko) 2015-11-18 2021-02-26 머크 샤프 앤드 돔 코포레이션 Pd1 및/또는 lag3 결합제
US20190127447A1 (en) 2016-05-02 2019-05-02 Ablynx N.V. Treatment of rsv infection
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
MX2019000554A (es) 2016-07-11 2019-09-19 Opko Biologics Ltd Factor vii de coagulación de acción prolongada y métodos para producir el mismo.
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
US20180303952A1 (en) 2017-03-09 2018-10-25 Cytomx Therapeutics, Inc. Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof
CN106756306B (zh) * 2017-03-10 2018-06-19 山东泰义金属科技有限公司 一种门窗用铝合金的加工方法
KR20180109272A (ko) 2017-03-27 2018-10-08 한양대학교 산학협력단 세포투과성 펩타이드와 ctCTLA4 펩타이드가 융합된 융합단백질을 유효성분으로 하는 염증성 호흡기 질환 예방 또는 치료용 약학 조성물
WO2019092452A1 (en) * 2017-11-13 2019-05-16 Crescendo Biologics Limited Molecules that bind to cd137 and psma
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
WO2019173771A1 (en) 2018-03-09 2019-09-12 Cytomx Therapeutics, Inc. Activatable cd147 antibodies and methods of making and use thereof
EP4034171A1 (en) 2019-09-23 2022-08-03 Cytomx Therapeutics Inc. Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof
CN113261532A (zh) * 2020-02-17 2021-08-17 中山大学 一种肺癌动物模型的构建方法
KR20200033828A (ko) 2020-03-20 2020-03-30 한양대학교 산학협력단 세포투과성 펩타이드와 ctCTLA4 펩타이드가 융합된 융합단백질을 유효성분으로 하는 염증성 호흡기 질환 예방 또는 치료용 약학 조성물
US20230279115A1 (en) 2020-04-22 2023-09-07 Mabwell (shanghai) Bioscience Co., Ltd. Single variable domain antibody targeting human programmed death ligand 1 (pd-l1) and derivative thereof
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
CN111820188B (zh) * 2020-08-04 2021-10-29 中山大学附属第一医院 一种类哮喘慢阻肺重叠气道炎症小鼠模型的建立方法及其应用
AU2021332460A1 (en) 2020-08-27 2023-04-06 Enosi Therapeutics Corporation Methods and compositions to treat autoimmune diseases and cancer
CN113624978B (zh) * 2021-04-06 2023-09-19 四川大学华西医院 通过检测肺泡灌洗液及血清白蛋白来评估急性呼吸窘迫综合征/急性肺损伤及预后的试剂盒
US20220396623A1 (en) 2021-05-18 2022-12-15 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
KR20230009623A (ko) 2021-07-09 2023-01-17 충남대학교산학협력단 폐 표적 25-하이드록시 콜레스테롤 나노하이브리드를 포함하는 covid-19 관련 사이토카인 폭풍 억제 조성물

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
JPH07506091A (ja) * 1992-01-13 1995-07-06 バイオゲン　インコーポレイテッド 喘息の処置
CA2430039C (en) * 2000-11-28 2014-01-28 Medimmune, Inc. Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US20030232048A1 (en) * 2002-03-19 2003-12-18 Xiao-Dong Yang Methods for treating chronic obstructive pulmonary disease (COPD)
US20080008713A1 (en) * 2002-06-28 2008-01-10 Domantis Limited Single domain antibodies against tnfr1 and methods of use therefor
PT1517921E (pt) * 2002-06-28 2006-09-29 Domantis Ltd Ligandos duplamente especificos com semi-vida no soro aumentada
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
AU2003270330B2 (en) * 2002-09-06 2009-07-30 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component C5
WO2004022718A2 (en) 2002-09-06 2004-03-18 Amgen, Inc. Therapeutic human anti-il-1r1 monoclonal antibody
JP2006523090A (ja) * 2002-12-27 2006-10-12 ドマンティス リミテッド リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
CA2522007A1 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Methods of preventing or treating respiratory conditions
SI1639011T1 (sl) 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
CN101133084A (zh) * 2004-12-02 2008-02-27 多曼蒂斯有限公司 采用白细胞介素-1ⅰ型受体拮抗剂治疗呼吸道疾病的方法
PL2068889T3 (pl) 2006-08-10 2020-06-29 Roy C. Levitt Anakinra do zastosowania do leczenia zespołu zarostowego zapalenia oskrzelików

Also Published As

Publication number Publication date
KR20080066962A (ko) 2008-07-17
US8129503B2 (en) 2012-03-06
BRPI0617771A2 (pt) 2011-08-09
MA29882B1 (fr) 2008-10-03
US20120114651A1 (en) 2012-05-10
IL190787A0 (en) 2008-11-03
US9629909B2 (en) 2017-04-25
CN101346397B (zh) 2013-10-23
WO2007049017A2 (en) 2007-05-03
ZA200803576B (en) 2009-08-26
US20100034831A1 (en) 2010-02-11
CA2626939A1 (en) 2007-05-03
EP1948694B1 (en) 2018-07-25
CR9933A (es) 2008-08-21
EP1948694A2 (en) 2008-07-30
US20170210814A1 (en) 2017-07-27
AU2006307733A1 (en) 2007-05-03
NZ567441A (en) 2012-08-31
MX2008005129A (es) 2008-10-23
EA014106B1 (ru) 2010-10-29
ES2688941T3 (es) 2018-11-07
TW200740848A (en) 2007-11-01
CN102302777A (zh) 2012-01-04
CN101346397A (zh) 2009-01-14
GB0521621D0 (en) 2005-11-30
JP2009512672A (ja) 2009-03-26
WO2007049017A3 (en) 2008-01-31
EA200800905A1 (ru) 2008-10-30
AU2006307733B2 (en) 2012-11-22
US20130309227A1 (en) 2013-11-21
US8497244B2 (en) 2013-07-30

Similar Documents

Publication Publication Date Title
NO20081836L (no) Tumor nekrose faktor reseptor 1 antagonister for behandling av respiratoriske sykdommer
CY1122533T1 (el) Ανακινρα για χρηση στην αντιμετωπιση συνδρομου αποφρακτικης βρογχιολιτιδας
JP2016040316A5 (no)
WO2006059108A3 (en) ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES
JP6099609B2 (ja) 肺炎症を低減するためのレボフロキサシンの吸入
CA2558212A1 (en) Interferon-beta for anti-virus therapy for respiratory diseases
WO2020086759A3 (en) Composition and method for treating the lungs
MEP30108A (en) Formoterol superfine formulation
BRPI0819932A2 (pt) composição, uso de uma composição, dispositivo nebulizador, inalador ou intranasal, processos para produzir uma composição farmacêutica e uma composição polipeptídica, e, uso de um tampão fisiologicamente aceitável.
ATE330589T1 (de) Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege
DE60216588D1 (de) Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen
Thipphawong et al. Analgesic efficacy of inhaled morphine in patients after bunionectomy surgery
DE602005026007D1 (de) Opioide zur behandlung von chronisch-obstruktiver lungenerkrankung (copd)
ME02495B (me) Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda
RU2006132040A (ru) Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей
JP2009513631A5 (no)
JP2013515022A (ja) 相乗的抗ウイルス組成物及びその使用
CN108366981B (zh) 用于治疗与间质性肺病相关的咳嗽的甲磺司特
TW201043225A (en) Antitumour combination comprising AVE8062 and sorafenib
EA200701077A1 (ru) Применение конъюгатов липидов при лечении заболеваний
JP7369523B2 (ja) 中等度～重度のインフルエンザの処置
WO2020031148A1 (en) Pharmaceutical composition, medicinal product and method of treatment of bronchopulmonary obstructive diseases
TWI253930B (en) Novel combination of loteprednol and beta2 adrenoceptor agonists
JP2009506029A5 (no)
RU2013118026A (ru) Карбонатные производные для лечения кашля

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application